RSV vaccine market to drop 64% post CDC decision (NYSE:PFE)

Healthcare analytics firm Airfinity cut its U.S. market forecast for respiratory syncytial virus (RSV) vaccines in older adults by as much as 64% this week after a panel of CDC experts narrowed their recommendations on RSV immunizations last month.

Airfinity revised its forecast following a CDC advisory committee meeting in June that recommended a single lifetime RSV vaccine for those aged 75 years and older. The CDC’s Advisory Committee on Immunization Practices (ACIP) also declined to recommend RSV vaccines for adults aged 60–74 who are not at an elevated risk of the disease.